BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

769 related articles for article (PubMed ID: 15934079)

  • 1. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
    Fitzgerald AA; Leclercq SA; Yan A; Homik JE; Dinarello CA
    Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.
    Kötter I; Wacker A; Koch S; Henes J; Richter C; Engel A; Günaydin I; Kanz L
    Semin Arthritis Rheum; 2007 Dec; 37(3):189-97. PubMed ID: 17583775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
    Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
    Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anakinra in refractory adult onset Still's disease].
    Vercoutere W; Starmans-Kool M; Peeters RM
    Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refractory adult onset Still's disease successfully treated with anakinra.
    Vasques Godinho FM; Parreira Santos MJ; Canas da Silva J
    Ann Rheum Dis; 2005 Apr; 64(4):647-8. PubMed ID: 15374853
    [No Abstract]   [Full Text] [Related]  

  • 6. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease.
    Naumann L; Feist E; Natusch A; Langen S; Krause A; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2010 Feb; 69(2):466-7. PubMed ID: 20107032
    [No Abstract]   [Full Text] [Related]  

  • 7. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.
    Chen DY; Lan JL; Lin FJ; Hsieh TY
    J Rheumatol; 2004 Nov; 31(11):2189-98. PubMed ID: 15517632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis and management of adult-onset Still's disease.
    Efthimiou P; Georgy S
    Semin Arthritis Rheum; 2006 Dec; 36(3):144-52. PubMed ID: 16949136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study.
    Nordström D; Knight A; Luukkainen R; van Vollenhoven R; Rantalaiho V; Kajalainen A; Brun JG; Proven A; Ljung L; Kautiainen H; Pettersson T
    J Rheumatol; 2012 Oct; 39(10):2008-11. PubMed ID: 22859346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of refractory adult-onset Still's disease treated with anakinra.
    Lahiri M; Teng GG
    Int J Rheum Dis; 2010 Aug; 13(3):e36-41. PubMed ID: 20704609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid-resistant adult-onset Still's disease which showed a quick response to methotrexate.
    Okamoto O; Oishi M; Fujiwara S
    J Dermatol; 2008 Feb; 35(2):106-10. PubMed ID: 18271807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum cytokine profiles in patients with adult onset Still's disease.
    Choi JH; Suh CH; Lee YM; Suh YJ; Lee SK; Kim SS; Nahm DH; Park HS
    J Rheumatol; 2003 Nov; 30(11):2422-7. PubMed ID: 14677188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy.
    Giampietro C; Ridene M; Lequerre T; Costedoat Chalumeau N; Amoura Z; Sellam J; Sibilia J; Bourgeois P; Fautrel B;
    Arthritis Care Res (Hoboken); 2013 May; 65(5):822-6. PubMed ID: 23225779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics, treatment, and outcome of adult onset Still's disease in southern Chinese.
    Mok CC; Lau CS; Wong RW
    J Rheumatol; 1998 Dec; 25(12):2345-51. PubMed ID: 9858428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective treatment of steroid refractory adult-onset Still's disease with anakinra.
    Maier J; Birkenfeld G; Pfirstinger J; Schölmerich J; Fleck M; Brühl H
    J Rheumatol; 2008 May; 35(5):939-41. PubMed ID: 18464320
    [No Abstract]   [Full Text] [Related]  

  • 16. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease.
    Chen DY; Lan JL; Lin FJ; Hsieh TY; Wen MC
    Ann Rheum Dis; 2004 Oct; 63(10):1300-6. PubMed ID: 15361391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease.
    Lovell DJ; Bowyer SL; Solinger AM
    Arthritis Rheum; 2005 Apr; 52(4):1283-6. PubMed ID: 15818707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory adult-onset still disease successfully treated with abatacept.
    Ostrowski RA; Tehrani R; Kadanoff R
    J Clin Rheumatol; 2011 Sep; 17(6):315-7. PubMed ID: 21869709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still's disease.
    Chen DY; Lan JL; Lin FJ; Hsieh TY
    Arthritis Rheum; 2005 Jun; 53(3):320-7. PubMed ID: 15934126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.